AEterna Zentaris
Quick facts
Marketed products
- Macrilen · Other
Macrilen works by binding to the growth hormone secretagogue receptor type 1, triggering a response that stimulates the release of growth hormone.
Phase 3 pipeline
- AEZS-108 / zoptarelin doxorubicin · Oncology
AEZS-108 is a conjugate of a GnRH agonist (zoptarelin) linked to the chemotherapy drug doxorubicin, designed to deliver cytotoxic payload selectively to GnRH receptor-expressing cancer cells. - AEZS-130 (formerly ARD-07) · Oncology
AEZS-130 is a selective androgen receptor (AR) antagonist that blocks androgen signaling in hormone-sensitive cancers. - Cetrorelix 78+78 · Oncology; Reproductive/Endocrinology
Cetrorelix is a gonadotropin-releasing hormone (GnRH) antagonist that suppresses luteinizing hormone and follicle-stimulating hormone to inhibit ovarian steroid production. - Cetrorelix Pamoate · Oncology; Reproductive Health
Cetrorelix pamoate is a gonadotropin-releasing hormone (GnRH) antagonist that blocks GnRH receptors to suppress luteinizing hormone and follicle-stimulating hormone secretion. - L-ARG+GHRH · Endocrinology / Metabolic disorders
L-arginine combined with growth hormone-releasing hormone (GHRH) stimulates endogenous growth hormone secretion to promote anabolic effects and tissue repair. - shark cartilage extract AE-941 · Oncology
AE-941, a shark cartilage extract, is thought to inhibit angiogenesis.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: